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Abstract
Artemisinin, from which the artemether component of Coartem® (artemether/lumefantrine, AL)
is derived,is obtained from the plant sweet wormwood (Artemisia annua) which has been used for
over 2,000 years as a Chinese herbal remedy. Artemisinin was first identified by Chinese researchers
as the active anti-malarial constituent of A. annua and its derivatives were found to be the most
potent of all anti-malarial drugs.Artemether acts rapidly,reducing the infecting parasite biomass by
approximately 10,000-fold per asexual life cycle. Lumefantrine, the other active constituent of AL,
acts over a longer period to eliminate the residual 100-100,000 parasites that remain after
artemether is cleared from the body and thus minimizes the risk of recrudescence.The two agents
have different modes of action and act at different points in the parasite life cycle and show a
synergistic action against Plasmodium falciparum in vitro. The combination of artemether and
lumefantrine reduces the risk of resistance developing to either agent, and to date there are no
reports of resistance to AL combined therapy in the malaria parasite that infects humans.Following
a unique partnership agreement between Chinese authorities and Novartis, the manufacturer of
AL, over 20 sponsored clinical studies have been undertaken in various malaria endemic regions
and in travellers.These trials have involved more than 3,500 patients (including over 2,000 children),
and led to identification of a six-dose, three-day regimen as the optimal dosing strategy for AL in
uncomplicated falciparum malaria. AL has consistently shown 28-day polymerase chain (PCR)-
corrected cure rates greater than 95% in the evaluable population, meeting WHO recommen-
dations.More recently,Novartis and the Medicines for Malaria Venture have worked in partnership
to develop Coartem® Dispersible, a new formulation designed specifically to meet the specific
needs of children with malaria.The dispersible tablets have shown similar high response rates to
those observed with crushed standard tablets of AL.A partnership agreement between Novartis
and WHO has seen over 250 million AL (Coartem®) treatments (75% for children) being distri-
buted to malaria patients in developing countries without profit,supported by training programmes
and educational resources.
Open AccessBackground
Since it first received international licensing approval in
1999, Coartem® (artemether/lumefantrine, AL) has become
a mainstay of malaria treatment worldwide and is
currently registered for use in almost 90 countries
worldwide. Since 2002 it has been included in the WHO
Model List of Essential Medicines, an index of priority
drugs that guides purchasing decisions by United Nations
agencies and many developing countries, and in 2007 it
was added to the WHO Model List of Essential Medicines
for Children. In 2004, Coartem® became the first fixed-
dose artemisinin combination therapy to be pre-qualified
by the WHO, and received approval from the Food and
Drug Administration in the US in April 2009.
The discovery of artemisinin
The rapid-acting component of AL, artemether, is a
derivative of artemisinin, a potent anti-malarial agent that
is effective against multi-drug resistant parasites [1].
Artemisinin is obtained from the Chinese herb sweet
wormwood (Artemisia annua). The first description of the
use of sweet wormwood dates from the year 168 BC,
when the plant was mentioned in a tomb of a member of
the Han dynasty for the treatment of 52 diseases; in the
year 1086 it was recommended in a Chinese compen-
dium of medicines for the management of fevers and
chills [2]. During the Vietnam War, the Chinese govern-
ment systematically searched for an anti-malarial
treatment from traditional Chinese medicine to support
the Vietnamese army, and in 1972 artemisinin was
identified as the active anti-malarial agent in A. annua [2].
Artemether (Figure 1) and other artemisinin derivatives
have a broader spectrum of activity than other anti-malarial
drugs, extending from the young ring stage of parasite
development through to the early schizont [3]. Artemisinin
derivatives proved to be the most potent of all anti-malarial
drugs, reducing the infecting parasite biomass by
approximately 10,000-fold per asexual life cycle i.e. every
two days [4]. Importantly, artemisinin derivatives also
markedly reduce gametocyte carriage, thereby limiting
malaria transmission [1, 5]. Several large-scale studies have
demonstrated excellent gametocyte clearance [6-9]; indeed,
in some trials no patient had gametocytes present two
weeks after the first dose of AL was administered [6-8].
Artemisinin-based treatment has shown significantly
greater gametocidal activity compared with other agents
[10, 11] and the widespread introduction of artemisinin-
based therapy is believed to have contributed to reduced
rates of malaria in sub-Saharan Africa.
Advantages of the artemether/lumefantrine
combination
Despite the potency of artemether, 100-100,000 residual
parasites remain when the drug is used alone for a three-
day treatment course, and as a result up to 10% of patients
experience recrudescence [4, 12]. It was recognized that
combination treatment which eliminated the final
parasites would be advantageous. The anti-malarial agent
lumefantrine (Figure 1), which was originally synthesized
by the Academy of Military Medical Sciences in Beijing
[2], was identified by researchers at the Academy as a
promising agent for combination with artemisinin. The
two agents have different modes of action and act at
different points in the parasite life cycle [1, 3].
Artemisinin derivatives, such as artemether, have multiple
mechanisms of action, including interference with
parasite transport proteins, disruption of parasite mito-
chondrial function, modulation of host immune function
and inhibition of angiogenesis [13]. Lumefantrine
prevents the detoxification of haem, such that toxic haem
and free radicals induce parasite death [1]. In vitro,
artemether and lumefantrine show a synergistic action
against  P. falciparum [14]. Additionally, the differing
pharmacokinetics of the two agents offer an advantage for
combination therapy. Artemether and its main active
metabolite dihydroartemisinin (DHA) are extremely
potent anti-malarials that reach peak concentration
quickly (at approximately two hours [3]) and are
Malaria Journal 2009, 8(Suppl 1):S3 http://www.malariajournal.com/content/8/S1/S3
Page 2 of 6
(page number not for citation purposes)
Figure 1
Chemical structures of artemether and lumefantrine.eliminated rapidly (elimination half-life 1-3 hours) [1, 3].
Lumefantrine is absorbed and eliminated more slowly
than artemether, with a terminal elimination half-life of
4-5 days [1]. As described in the subsequent chapter
‘Understanding the Pharmacokinetics of Coartem®’, these
characteristics work synergistically: the rapidly-absorbed
artemether and DHA achieve a fast reduction in parasite
biomass and prompt symptomatic improvement, while
the lumefantrine concentrations that persist in the blood
after the three-day treatment course eliminate any
remaining parasites to prevent recrudescence [3].
The combination of artemether and lumefantrine would
also be expected to restrict the development of drug
resistance to either agent. Combination therapy is now
widely accepted as the way forward to slow the rapid
emergence and spread of resistance to malaria, and to
increase the useful therapeutic life of anti-malarial drugs.
Indeed, in 2006 WHO called for manufacturers to stop
selling monotherapy artemisinin treatments in an
attempt to prevent malaria parasites developing resistance
to the drug [15]. Concomitant administration of arte-
mether and lumefantrine reduces the chance of survival
by a resistant organism, since their different sites of action
mean that mutations resistant to both agents would be
required for the organism to survive [4]. This advantage
only applies to drug combinations in which the organism
is not already resistant to one or more of the drugs, which
was the case for both artemether and lumefantrine. To
date, there are only two recorded cases of resistance to
artemisinin derivatives, both reported in patients
receiving artesunate monotherapy in Western Cambodia
[16] a region that has seen approximately 30 years of
artemisinin use in various doses and formulations and
perhaps the greatest exposure to artemisinin of anywhere
in the world. While parasites from these two patients
showed reduced susceptibility in vitro, the authors
commented that artemisinin resistance does not seem to
be a widespread epidemiologic phenomenon and in a
subsequent publication by White et al pointed out that
malaria parasites from Western Cambodia are no more
resistant in vitro than parasites from other regions [17].
No cases of resistance have been reported for patients
receiving artemether/lumefantrine together, in AL.
Lumefantrine, unlike other companion drugs used in
artemisinin-based therapies, was never used as
monotherapy prior to combination with artemether in
AL, and has thus not been exposed to the risk of resistance
that this entails. It is known that long elimination times
facilitate the spread of resistant parasites once a mutation
arises [5], because this increases the chance of a second,
unrelated infection while drug concentrations are low and
the likelihood of within-patient selective pressure when
an infection is not eradicated from the body [4]. The short
elimination half-life of artemether means that it has a low
potential for selection of resistant parasites [1]. While the
elimination half-life of lumefantrine is longer (4-5 days),
it is markedly shorter than the half-lives of agents such as
mefloquine (2-3 weeks) and choloquine (1-2 months),
against which significant resistance has emerged [5], and
piperaquine, for which drug resistance has also been
reported and which has an elimination half-life of approxi-
mately 17 days in children with malaria [18].
The clinical development programme
During the 1980s and 1990s, researchers at the Beijing
Academy of Military Medical Sciences investigated
combined administration of artemether with lumefan-
trine. From 1994 onwards, this work was undertaken in
collaboration with Novartis, the manufacturer of AL
(Coartem®), in the first joint development programme of
its type in Chinese history. Preclinical studies indicated
that a 1:6 fixed combination of artemether and
lumefantrine was well tolerated even at doses 10 times
higher than those used in subsequent clinical trials [3],
and based on the results from clinical trials in several
hundred patients it was concluded that a 1:6 weight/
weight ratio was the optimum combination [3]. These
early studies showed that the AL combination was an
effective and well-tolerated treatment for uncomplicated
falciparum malaria [19-22].
Over 20 clinical studies of AL supported by Novartis have
now been undertaken in various malaria endemic regions
and in travellers (Figure 2). In total, 3,599 patients, inclu-
ding 1,572 adults and 2,027 children, have taken part in
these trials. Additionally, approximately 45 independent
clinical trials have been published in the scientific
literature. These have each used a twice-daily regimen that
maintained the blood concentration of artemether above
the minimum effective concentration [1], to ensure that
the infecting parasites are all exposed to high levels of
artemether when they are in the middle third of their
lifecycle – the point at which they are most susceptible to
anti-malarial agents [23]. Early trials using a four-dose
regimen of AL, with a twice-daily regimen that
maintained the blood concentration of artemether above
the minimum effective concentration [1], showed
excellent parasite and fever clearance with high cure rates
[19, 21, 22]. Subsequently, however, a randomized, double-
blind study was undertaken in Thailand, in which 359
adults and children with uncomplicated falciparum
malaria received either a four-dose or six-dose twice-daily
regimen of AL [24]. While parasite and fever clearance
time were similar with either a four- or six-dose schedule,
six doses resulted in a 28-day PCR-corrected cure rate of
>95% in evaluable patients, significantly higher than that
seen in patients given a four-dose course (83.3%,
p<0.001). Tolerability was unaffected by use of a six-dose
regimen. On this basis, studies have since employed the
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randomized trials in the same geographic region [25, 26]
and elsewhere [27] have confirmed PCR-corrected cure
rates above 95% among evaluable patients [19, 20],
meeting the WHO target response rate [5].
A discussion of more recent trial results is included in ‘The
clinical efficacy of artemether/lumefantrine (Coartem®)’ in
this supplement [28].
The evaluation of AL in specific clinical settings is
ongoing. One prospective, randomized trial involving
over 200 patients is currently underway in Columbia with
the aim of confirming that AL does not affect auditory
function, while an observational pregnancy study is being
conducted at four antenatal clinics in Zambia to assess
outcomes in mothers and newborns after use of AL
therapy during the second or third trimester. In a rural
area of southern Tanzania, an epidemiological study is
being carried out to investigate the impact of the intro-
duction of AL as a national treatment policy on all-cause
mortality, malaria transmission, safety and adherence in
infants and children younger than five years old.
Development of Coartem® Dispersible
Until recently, there was no WHO-endorsed paediatric
formulation for the treatment of malaria. Working in
partnership, Novartis and the Medicines for Malaria
Venture (MMV) have developed a formulation of AL
tailored to the needs of children with P. falciparum
malaria. The previous standard of care, crushed standard
tablets of AL, achieved 28-day PCR-corrected cure rates of
>95% among evaluable patients [6, 25, 29], but was
inconvenient for caregivers and difficult to administer to
sick children, while the crushing process risked loss of
drug and the bitter taste meant that children might spit it
out. The new dispersible formulation received its first
approvals for use in 2008, followed by further approvals
including Switzerland in 2009, and was pre-qualified by
the WHO in 2009. (See ‘Dispersible formulation of
artemether/lumefantrine: specifically developed for infants and
young children’ in this supplement for more details) [30].
Distribution of AL to malaria endemic countries
Following a ten-year agreement with WHO in 2001, the
manufacturer Novartis made AL (Coartem®) available
without profit for distribution through WHO in malaria-
endemic developing countries. More than 250 million
treatments have been provided through this without-
profit arrangement, 75% of which were for children. In
2008 alone, 74 million treatments were distributed. This
unexpected demand for AL has necessitated a dramatic
growth in commercial farming of high-quality A. annua
plants in Kenya and China, as well as the establishment of
extensive new production facilities in China, Africa and
the US. In addition, the widespread adoption of AL has
been supported by a series of training programmes and
educational materials for health professionals and
patients or carers, to help ensure optimal prescribing and
adherence to the AL regimen.
Home-based management using AL
One vital area of research is the development of strategies
for the use of home-based malaria management using AL
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Figure 2
Overview of the clinical development programme for AL.[31-34] in order to address the problem of poor access to
health centres particularly in poor, rural areas [35]. There
are obstacles to be overcome, including misdiagnosis at
home on the basis of symptoms alone, over-prescribing
with risk of resistance, and achieving adequate availability
of AL for home treatment [36]. A study by Dunyo et al has
shown, however, that the accuracy of presumptive
diagnoses by carers and health centres was similar when
confirmed by parasitological analysis, and the diagnosis
was typically made three days earlier at home, helping to
prevent complications that arise from persistence of
symptoms and progression to high levels of parasitaemia
[37]. Intervention studies in which AL was made available
locally for home management have shown encouraging
results, providing prompt treatment [31, 34], with good
adherence to the correct prescribing regimen [32], while
reducing the case burden at health facilities [33]. The risk
of over-prescription of AL can, however, can be an issue
with carer administration [34], and distribution through
trained community health workers - if available - may
help to ensure appropriate prescribing, especially if the
community team is equipped with rapid diagnostic
testing (See ‘Impact of large-scale deployment of artemether/
lumefantrine on the malaria disease burden in Africa: case
studies of South Africa, Zambia and Ethiopia’ for more
details [38].)
Conclusion
AL has had a remarkable journey to the clinic, from an
ancient Chinese herbal remedy to a modern medicine
that meets the most stringent drug approval criteria, and
over 250 million Coartem® treatments have now been
delivered. A long series of clinical trials has assessed the
efficacy, safety and pharmacokinetics of AL – and more
recently the dispersible formulation of AL – in a wide
range of geographic regions and patient types, achieving
cure rates higher than 95% among evaluable patients,
with good tolerability. Ongoing investigations continue
to ensure optimal safety and to identify the best routes for
prescribing and distribution of AL, while AL continues to
be provided in developing countries through non-profit
production from Novartis with distribution via WHO.
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